期刊文献+

GEMOX方案治疗晚期胰腺癌的临床护理体会 被引量:2

下载PDF
导出
摘要 目的探讨吉西他滨联合奥沙利铂治疗晚期胰腺癌患者的临床护理体会。方法回顾分析42例均经病理学检查确诊的晚期胰腺癌患者,应用吉西他滨800~1200mg/m2,静脉滴注30min,d1、d8;奥沙利铂135mg/m2,静脉滴注2h,d1,每21~28d为一个周期。在用药期间注重心理护理及其健康教育,注意观察化疗药物的特殊不良反应;并结合相应的护理对策及方法预防并发症的发生及减轻不良反应。结果 42例患者出现骨髓抑制24例,10例患者出现肝功能轻度受损,20例外周神经毒性发生,患者都有不同程度的恶心、呕吐等消化道反应,无一例死亡。结论胰腺癌生存率虽低,应用GEMOX方案治疗晚期胰腺癌患者安全,近期有效率及临床获益率较高,所以在用药期间应特别注意观察患者不良反应与护理。
出处 《海南医学》 CAS 2012年第6期143-144,共2页 Hainan Medical Journal
  • 相关文献

参考文献7

二级参考文献30

  • 1Chen, Jian-Hua,Ni, Run-Zhou,Xiao, Ming-Bing,Guo, Ji-Guang,Zhou, Jia-Wei.Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue[J].Hepatobiliary & Pancreatic Diseases International,2009,8(2):193-200. 被引量:27
  • 2许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 3胡佩诚.心理治疗[M].北京:中国医药科技出版社,2006:147-166.
  • 4Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [J]. J Clin Oncoh 1997, 15(6):2403-2413.
  • 5Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase Ⅲ trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group [J]. J Clin Oncol, 2007, 25(16):2212-2217.
  • 6Heinemarm V, Quietzsch D, Gieseler F, et al. Randomized phase Ⅲ trial of gemcitabine plus cisplatin with gemcitabine alone in advanced pancreatic carcinoma [J]. J Clin Oncol, 2006, 24(24) : 3946-3952.
  • 7Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase Ⅲ trial [J]. J Clin Oncol, 2005, 23(15) :3509-3516.
  • 8Berlin JD, Catalano P, Thomas JP, et al. Phase Ⅲ study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 [J].J Clin Oncol, 2002, 20(15): 3270-3275.
  • 9Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unreseetable pancreatic cancer: a randomized trial[J].J Clin Oncol, 2001,19(15): 3447-3455.
  • 10Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic caneer[J]. Br J Cancer, 2002, 87( 2): 161-167.

共引文献64

同被引文献6

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部